►
From YouTube: Open Source Antibiotics Science Update Mar 18th 2022
Description
Weekly open project meeting for Open Source Antibiotics Series 2.
Full Project: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles
Relevant GitHub Issue: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles/issues/113
On the call: Professor Matthew Todd, Dr Edwin Tse, Dr Daniel Gedder, Alex Vaidenanu (UCL), ?? (NEU), Dr Chris Swain (Cambridge Medchem Consulting).
A
Get
started
all
right,
hi
everyone
thanks
for
joining
this
is
open
source
antibiotics
meeting
on
friday,
the
18th
of
march.
So
we
have
a
short
meeting
today
that
is
intended
to
focus
on
a
couple
of
things.
One
is
going
to
be,
I
think,
daniel's
recent
chemistry,
two
is
going
to
be
alex's
talks
and
dna
binding
work.
I
think
she'll
be
joining
us
in
a
minute.
Three
was
going
to
be
lee
graves's
mechanism
action
work.
I
think,
he's
not
quite
ready
to
come
to
the
meeting
to
present
the
data
today.
A
So
the
plan
is
currently
to
talk
about
that
at
the
next
meeting,
which
will
be
on
april
the
1st,
and
that
is
not
a
joke.
It
will
be
on
april
1st,
no
no
daniel.
You
called
it
lie
day
earlier.
That
was
really
amusing.
So
in
brazil,
it's
called
july
day,
which
I
I
prefer
right,
but
so
it'll
be
april
the
first
it
will
be.
A
B
A
B
B
B
B
A
A
A
A
A
A
C
So
last
sorry-
I'm
not
here
too
often,
but
last
time
we
were
wondering.
Why
is
it
that
these
compounds
are
so
toxic
and
we
hypothesize
that
maybe
they're
binding
to
dna?
So
what
I've
been
doing
was
to
test?
I
have
a
hypothesis
and
the
way
I've
been
doing
this.
I
designed
some
dna
sequences
which
are
complementary
to
each
other
and
they
have
a
fluorescent
donor
at
one
end
fluorescent
venture
at
the
other
end.
So
when
the
sequence
is
hybrid
well
annealed,
then
it
will
be
complemented
to
each
other.
C
So
there
will
be
no
fluorescence.
If
there's
something
that
comes
and
interferes
with
the
binding,
then
we
should
see
a
change
in
fluorescence.
So
what
I'm
showing
on
this
slide
is
what
happens
to
when
you
just
sort
of
cycle
the
the
molecular
beacon,
as
it's
called
through
different
temperatures,
and
from
this
you
can
get
a
curve.
C
B
C
C
So
you
can
see
there's
a
clear
shift
towards
the
right,
suggesting
that
the
oxalousin
is
stabilizing
the
dna
duplex
which
results
in
it
melting
at
a
higher
temperature.
So
this
makes
sense
to
me,
so
we
can
just
go
ahead
and
test
our
some
molecules
and
I
went.
I
decided
to
go
with
one
h1861,
so
h1
is
very
toxic.
Eight
six
on
eight
six
one
is
not
toxic
and
then
tamoxifen
and
doxorubicin
dimoxifen
is
another
control
from
the
coat
protocol.
A
C
So
I
have
a
few
other
well,
I
I
basically
bought
three
different
dna
sequences.
You
can
design
these
as
you
well,
there
are
some
guidelines,
but
and
depending
on
how
much
gnc
they
have,
they
have
higher
smaller
melting
temperatures.
So
this
one
that
I've
tested
here
is
the
one
that
this
melts
most
readily.
I
can
see
whether
with
it
with
this
dna
sequence,
that
is
more
stable,
whether
that
makes
a
difference
at
all.
C
A
C
C
C
A
A
B
A
A
C
E
C
A
C
A
Great,
I
mean
the
the
the
first
diagram
you
had,
you
know
showed
an
annealed
section
and
then
a
loop
which
wasn't
annealed,
and
I
guess
that
would
also
be
important.
So
so
there
is
double
strength
in
the
middle,
but
there's
a
cereal
there's
a
bit
where
there
isn't,
whether,
where
it
curves
around.
I
suppose-
and
I
guess
that's:
okay.
A
A
C
A
A
Right:
well,
that's
really
good
yeah,
if
you
wouldn't,
if
you
wouldn't
mind,
just
checking
on
the
going
down
data
and
then,
if
you
wanted
to,
if
you're
happy
to
to
when
you're
happy
to
send
a
a
few
of
those
slides
over,
we
can
post
them
somewhere.
So
people
can
have
a
look
and
we
can
see
if
anyone's
got
any
other
interpretations.
C
C
A
Yeah,
no,
I
mean
we've
been
sort
of
tweaking
the
various
diagrams
and
data
and
stuff,
because
we
really
want
to
you
know,
publish
something
and
and
and
make
sure
that
all
your
efforts
are
appropriately
recognized
by
author
shaman
on
paper.
So
whenever
you
can
get
those
to
us,
we
can
fold
those
in
yeah
awesome
all
right.
Thank
you!
So
much
it's
really
good
and
then
just
in
the
last
few
minutes
maria
did
you
want
to
have
a
go
pretending's
coming
again.
Oh.
E
D
Okay,
so
I'm
working
on
these
two
analogues
and
the
differences
are
ongoing.
So
I
have
this
because
I'm
working
on
both
of
them
and
I
think
that
in
a
couple
of
weeks
you
should
be
ready
and
in
this.
Meanwhile,
I
want
to
ask
you
if
you
are
also
still
interested
in
the
molecule
with
the
cycle
of
the
build,
because
when
we
stand
in
the
plastic
box
of
molecules,
these
molecules
was
not
included,
because
I
had
some
purification
issue.
But
if
you
are
still
interested
in
athletes.
A
A
It
would
be
an
it's
a
nice
analog
for
sure
I
think
it
I
mean
it's
a
it's
a.
I
guess
the
the
cycler
profile
is
something
that
we
haven't
really
had
in
the
series
before
right.
As
far
as
I'm
aware.
So,
if
you
are
not
going
to
spend
like
a
massive
amount
of
time
on
that,
it
would
be
nice
to
have
if
you're
going
to
be
spending
like
days
and
days
on
it.
Don't.
A
Fantastic
and
sorry,
the
two,
the
two
molecules
on
the
bottom
right
of
your
of
your
slide.
There
are
your
current
targets,
so
that's
the
on
the
bottom
yeah
on
the
bottom
right,
so
the
the
imidazole
version
and
then
the
what
is
that
pyramidal
version,
so
bottom
right
area
slide
the
bottom
right
molecule
and
the
one
above
it.
A
Yeah
yeah,
that's
right,
okay,
but
those
look
very
interesting
for
evaluation.
For
sure
I
guess
I
wasn't
aware
you
were
making
those.
Maybe
I
should
be
aware
of
you
making
this,
but
I
wasn't
aware
you're
making
those,
because
those
are
quite
nice,
so
you're
but
you're
currently
progressing
through
these
you've
got
300
megs
of
one
and
70
mixed
to
another
and
you're
trying
to
get
to
the
end
of
both
of
those.
Is
that
right?